Clinical Trials

220 enrolled 16 charts 1 FDA

Phase 2 Active not recruiting

Melanoma

NCT00937937 2026-03-20

Dinaciclib in Treating Patients With Stage IV Melanoma

72 enrolled 14 charts

Phase EARLY_PHASE1 Completed

Melanoma

NCT03276832 2026-03-19

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

7 enrolled 11 charts

BreastCNSDermatologicOther hematologic neoplasmThoracic

Melanoma

NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Phase 1/2 Terminated

8 enrolled 13 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

378 enrolled 15 charts 2 FDA

Uveal Melanoma, Melanoma

NCT06221397 2026-03-16

LEGIT_MC_EVCDA

Completed

105 enrolled 15 charts

DermatologicGastrointestinalGenitourinaryGynecologic

Disease, Melanoma

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Active not recruiting

71 enrolled 9 charts

Melanoma

NCT02362594 2026-03-05

MK-3475-054

1,019 enrolled 16 charts 2 FDA

Phase 2 Active not recruiting

Melanoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

921 enrolled 48 charts 2 FDA

Melanoma

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

1,150 enrolled 6 charts

Melanoma

NCT04093323 2026-02-25

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2 Terminated

1 enrolled

Melanoma

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1/2 Completed

281 enrolled 44 charts

Melanoma, Neoplasms

NCT01659151 2026-02-20

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

17 enrolled 11 charts

Melanoma, Neoplasm Metastasis

NCT04526730 2026-02-20

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

17 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

1,673 enrolled 19 charts

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

Melanoma

NCT03820986 2026-02-09

LEAP-003

Phase 3 Completed

674 enrolled 21 charts